TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03811561
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
Study: NCT03105466
Drug: Tobradex eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02483767
Drug: standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
Study: NCT03007888
Drug: IPX203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Release capsules containing carbidopa-levodopa flexible dosing
Study: NCT02926053
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study: NCT00300430
Drug: ABT-335 and rosuvastatin calcium
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
Study: NCT00300430
Drug: ABT-335 and simvastatin
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 135 mg plus simvastatin daily, 52 weeks
Study: NCT00471614
Drug: NucleomaxX (contains uridine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated doses of NucleomaxX tid
Study: NCT02589600
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Annual intravenous 5.0 mg
Study: NCT00368290
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills for 8 weeks
Study: NCT03269162
Drug: Jinfukang Koufuye
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30ml per time, tid, po (d6-21, q21)
Study: NCT03044574
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
Study: NCT02813460
Drug: Formulation B (ALS-008176)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
Study: NCT02813460
Drug: Formulation D (ALS-008176)
Normalized name: Rho(D) Unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
Study: NCT02813460
Drug: Formulation F (ALS-008176)
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
Study: NCT02813460
Drug: Formulation G3 (ALS-008176)
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Study: NCT02813460
Drug: Formulation H1 (ALS-008176)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT02813460
Drug: Formulation H2 (ALS-008176)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT03690206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for glepaglutide
Study: NCT02557074
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
Study: NCT01402427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial administration of 10 mL saline.
Study: NCT01275521
Drug: Optimized medical BPH treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of the medical therapy according to recent guidelines
Study: NCT03365388
Drug: Aerzhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
Study: NCT03548454
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open label prescription
Study: NCT03231683
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study: NCT03213769
Drug: topical coenzyme Q10 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
Study: NCT00592774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg titrated up to 8 mg maximum; taken once daily.
Study: NCT00200200
Drug: HAI plus systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
Study: NCT03323476
Drug: Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Study: NCT03289520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01587768
Drug: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
Study: NCT00832039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
Study: NCT04208061
Drug: DRV/COBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
Study: NCT01663532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02469298
Drug: Placebo To Match GSK1325756
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be supplied as capsule shaped white film coated placebo tablet for oral use
Study: NCT00517816
Drug: RG1671
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)
Study: NCT04507373
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg oral daily for 10 weeks
Study: NCT01761071
Drug: topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Study: NCT01761071
Drug: topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
Study: NCT00617669
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral once daily dose
Study: NCT00617669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablet once daily
Study: NCT01460199
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00649259
Drug: Ditropan XL® Tablets 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x10mg, single dose fed
Study: NCT02875574
Drug: Any treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
Study: NCT02127268
Drug: Thymosin-α1
Approvals — FDA: no, EMA: no, PMDA: no
Description: with Thymosin-α1 1.6mg twice a week
Study: NCT03218683
Drug: AZD5991
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
Study: NCT03960450
Drug: BOS-475
Normalized name: BOS TAURUS EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream
Study: NCT03960450
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream
Study: NCT03790423
Drug: Injection of 18F-ASIS
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
Study: NCT02373072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects completing all three treatment periods will be receiving placebo once.
Study: NCT01313273
Drug: Non steroidal anti androgens and LHRH-a
Normalized name: Anti-androgens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
Study: NCT00134784
Drug: [123I]B-CIT SPECT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess \[123I\]B-CIT SPECT imaging
Study: NCT02732197
Drug: Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
Study: NCT02732197
Drug: No sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parturients did not receive any type of sedation after spinal anesthesia.
Study: NCT00762424
Drug: Flowmax
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg once a day until stone passage total = 9 tablets
Study: NCT00762424
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cornstarch
Study: NCT01347580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by oral Ticagrelor loading dose (180 mg)
Study: NCT02605044
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02397499
Drug: LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02397499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03416062
Drug: Remaxol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
Study: NCT03550859
Drug: Telmisartan/Rosuvastatin 40/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
Study: NCT02885259
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: human immunoglobulin and one vial of recombinant human hyaluronidase
Study: NCT02587000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01270659
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet 100 mcg once
Study: NCT01270659
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet 200 mcg once
Study: NCT03860935
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active control administered orally twice daily (BID)
Study: NCT01485588
Drug: hI-con1™ 300µl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Study: NCT00266851
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg x 3 days, then 600 mg weekly x 11 weeks
Study: NCT00266851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01661088
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1.
Study: NCT00246571
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
Study: NCT00246571
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248.
Study: NCT01012648
Drug: HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Resuscitation
Study: NCT02331095
Drug: Anticoagulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
Study: NCT02552394
Drug: huJ591
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
Study: NCT04469829
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 15 mg/week
Study: NCT03163602
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access flap and debridement
Study: NCT02024152
Drug: JDP-205 IM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02024152
Drug: Control: Zyrtec
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04454619
Drug: Hand antisepsis with Clorhexidine and solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study: NCT00000477
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04549207
Drug: Bone modifying agent
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of bone modifying agent
Study: NCT00744354
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 30mg/m2, Day 4, each cycle
Study: NCT04040907
Drug: XNW3009
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNW3009 is a small molecule hURAT1 inhibitor
Study: NCT04040907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and active drug will have the same appearance
Study: NCT00799773
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
Study: NCT02513693
Drug: Standard neuromuscular blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
Study: NCT02513693
Drug: Deep neuromuscular blockade
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
Study: NCT03758885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single oral administration
Study: NCT02359175
Drug: Fentanyl in epidural catheter
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl to be given in epidural catheter
Study: NCT02736409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo dose
Study: NCT02359175
Drug: Oral Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol to be given orally
Study: NCT02359175
Drug: Oral NSAID
Normalized name: Ansaid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID to be given orally
Study: NCT02359175
Drug: Oral opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids to be given orally
Study: NCT02359175
Drug: Placebo (for oral opioids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to be given instead of oral opioids
Study: NCT03771898
Drug: SHP611
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
Study: NCT03520075
Drug: ASTX029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Described above
Study: NCT04528355
Drug: data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
Study: NCT03492840
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
Study: NCT03253471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Match AL-611
Study: NCT01221844
Drug: FerroGrad by Abbott
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
Study: NCT00416897
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02720094
Drug: TDF/FTC tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/200 mg fixed-dose combination tablets
Study: NCT02720094
Drug: Placebo for TDF/FTC tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02720094
Drug: Placebo for CAB LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Study: NCT00282464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
Study: NCT03748043
Drug: Ferric Hydroxide Polymaltose
Normalized name: ferric hydroxide
DrugBank: Ferric hydroxide (DB13423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron